| Document |
Document Title |
|
WO/2013/073648 |
The purpose of the present invention is to produce an anti-inflammatory functional agent from a raw material that contains no major food allergen and can be used widely as a food material. An anti-inflammatory functional agent for oral a...
|
|
WO/2013/074320 |
Disclosed herein is a pharmaceutical composition comprising a pain-relieving anticonvulsant and an alpha-2B receptor agonist. The composition is effective for treating chronic pain, and methods of treating chronic pain using the composit...
|
|
WO/2013/073577 |
[Problem] To provide a compound which has a D-amino acid oxidase (DAAO) inhibitory effect and is useful, for example, as a prophylactic and/or therapeutic agent for schizophrenia and neuropathic pain. [Solution] The inventors have achiev...
|
|
WO/2013/072896 |
The present invention is related to variants of mycolactones of formula (I), processes for the preparation thereof, pharmaceutical compositions thereof and their use in modulating inflammation, immunity and pain. Y-O-W (I), wherein Y and...
|
|
WO/2013/072390 |
The invention relates to substances which act as selective ligands of nuclear receptors of the PPAR beta/delta sub-type and can be used for treating PPAR beta/delta transmitted illnesses. The substances according to the invention act as ...
|
|
WO/2013/072825 |
The present patent application is directed to bicyclic compounds of formula (I) or pharmaceutically acceptable salt thereof as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (m PGES-1) enz...
|
|
WO/2013/074738 |
Ligand-specific HVEM variants, compositions comprising such variants, and methods of treating inflammatory diseases comprising administering such variants, are provided.
|
|
WO/2013/070606 |
The present invention provides method of treating or lessening the severity of a disease selected from spondyloarthropathy, systemic lupus erythematosus, rheumatoid arthritis, or any combination thereof comprising the administration of a...
|
|
WO/2013/068463 |
The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with an N-cyclic group as vanilloid receptor ligands formula (S) to pharmaceutical compositions containing these co...
|
|
WO/2013/070898 |
Novel compositions which are useful in the treatment of mammals for the reduction of inflammation, especially in the gut, and which comprise an aqueous extract of an agricultural product. Preferred compositions comprise an aqueous extrac...
|
|
WO/2013/070236 |
The present invention relates to compositions and methods for treatment of internal and/or external hemorrhoids, wherein the treatment includes topically administering to a subject a composition comprising from 0.3% to 0.7% of S-2'- [2-(...
|
|
WO/2013/068462 |
The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives of formula (R) bearing a phenyl moiety substituted with an N-containing group as vanilloid receptor ligands, to pharmaceutical compositions containing ...
|
|
WO/2013/070659 |
Provided herein are compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as pain, neurological disorders, psychiatric disorders, ...
|
|
WO/2013/070617 |
The present invention relates generally to the co-administration of an opioid agonist compound and an analgesic compound. In addition, the invention relates to, among other things, dosage forms for co-administration of an opioid agonist ...
|
|
WO/2013/069404 |
The purpose of the present invention is to provide a therapeutic agent for joint diseases, which has an activity of preventing the destruction of articular cartilages and has a high therapeutic effect. According to the present invention,...
|
|
WO/2013/068626 |
The use of a pentacyclic triterpene in the production of a pharmaceutical or neutraceutical composition to prevent or to treat a myocardial inflammatory disease, preferably acute or subacute myocarditis, to prevent or to treat a disease ...
|
|
WO/2013/068458 |
A series of thiazolo[5,4-d]pyrimidine derivatives of formula (I) or an N-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof: (I) Q represents a group of formula (Qa), (Qb), (Qc), (Qd) or (Qe) are beneficial in the tr...
|
|
WO/2013/068461 |
The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives of formula (Q) as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the trea...
|
|
WO/2013/071203 |
The present invention relates to novel 2,5-dioxoimidazolidin-l-yl-3- phenylurea derivatives of formula I, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-f...
|
|
WO/2013/068464 |
The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with a S02-containing group as vanilloid receptor ligands, to pharmaceutical compositions containing these compound...
|
|
WO/2013/067612 |
The present invention relates to the development of a pharmaceutical composition characterized by comprising triancinolone, bupivacaine and ethanol in the form of a suspension, the use thereof characterized by being for the preparation o...
|
|
WO/2013/067710 |
Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.
|
|
WO/2013/068902 |
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti- M-CSF antibodies ...
|
|
WO/2013/068467 |
The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives bearing a phenyl moiety substituted with a CO-containing group as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds...
|
|
WO/2013/067578 |
Heterocyclic compounds that modulate C3a receptors and their use in the treatment or prevention of inflammatory diseases, infectious diseases, cancers, metabolic disorders, obesity, type 2 diabetes, metabolic syndrome and associated card...
|
|
WO/2013/064445 |
The present invention relates to the use of novel compounds of formula (I): wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory dise...
|
|
WO/2013/064468 |
Disclosed are compounds of Formula (I), useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of makin...
|
|
WO/2013/065825 |
Provided is a cationic lipid expressed in the following formula (I), which facilitates introduction of a nucleic acid into a cell, a composition containing the cationic lipid and the nucleic acid, a method for introducing the nucleic aci...
|
|
WO/2013/066179 |
The invention relates to a pharmaceutical composition comprising liposomes composed of non-charged vesicle-forming lipids, optionally including not more than 10 mole percent of negatively charged vesicle- forming lipids and/or not more t...
|
|
WO/2013/064031 |
Disclosed are an N-benzylaniline derivative and uses thereof. The derivative is a compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound has an action of protecting against cerebral ischemia/reperfu...
|
|
WO/2013/064884 |
The present disclosure provides substituted pyridine and pyrimidine compounds of Formula (I) : A1-X-A2-Z-R1 (I) and the pharmaceutically acceptable salts, solvates and prodrugs thereof, wherein A, X, A, Z, and R are defined as set forth ...
|
|
WO/2013/064153 |
The present invention relates to novel depot formulations (prodrugs) comprising an immobility promoting unit linked via an ester to an active pharmaceutical ingredient, i.a. common NSAIDs. The novel depot formulations are suitable for in...
|
|
WO/2013/064508 |
The invention relates to novel polyethylene glycol (PEG) based prodrug of Adrenomedullin, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for producing medicame...
|
|
WO/2013/067084 |
Silylated nitrones and methods of detecting and/or superoxide using silylated nitrones are disclosed herein.
|
|
WO/2013/060179 |
Disclosed are acyltetrahydro-β-carboline small molecule organic compounds represented by structural formula (I) or hydrates or pharmaceutically acceptable salts thereof, and use of the present compounds or pharmaceutical compositions th...
|
|
WO/2013/063127 |
The present application provides novel compounds and methods for preparing and using these compounds. These compounds are useful in treating pain, itch, overactive bladder and/or interstitial cystitis in patients by administering one or ...
|
|
WO/2013/062027 |
The invention according to the present application provides a therapeutic or prophylactic agent for diseases including mood disorders, anxiety disorders, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eatin...
|
|
WO/2013/060303 |
Provided are polypeptides for inhibiting angiogenic activity, the source of said polypeptides being placental growth factor-1. Also provided are derivatives of the polypeptides, nucleic acid molecules for encoding same, a pharmaceutical ...
|
|
WO/2013/062344 |
The present invention relates to a novel hydroxamate derivatives, more specifically, to novel hydroxamate derivatives having inhibitory activity against Histone Deacetylase (HDAC), isomers thereof, pharmaceutically acceptable salts there...
|
|
WO/2013/061004 |
The present invention relates to novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds corresponding to the following general formula (I): , to the pharmaceutical compositions containing these compounds and also to the use of...
|
|
WO/2013/063004 |
Devices and methods for administering a therapeutic agent, comprising an implantable delivery device. Exemplary embodiments comprise a reservoir in fluid communication with a channeled member, and a solid matter therapeutic agent dispose...
|
|
WO/2013/063557 |
A method of treating an IL-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the SEFIR domain of IL-17R to th...
|
|
WO/2013/061816 |
The present description discloses a novel biologically active ingredient of manuka honey. Specifically, the present description discloses a compound represented by formula (AA). (In the formula, each of R1, R2 and R3 independently repres...
|
|
WO/2013/063458 |
This document relates to inhibitors of G protein coupled receptor 6 kinase (GRK6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.
|
|
WO/2013/061005 |
The present invention relates to novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds, represented by the following general formula (I): the pharmaceutical compositions containing these compounds and the use of these compoun...
|
|
WO/2013/062424 |
The invention relates to a method and composition for the treatment of pain and / or inflammation, especially neuropathic pain and neurogenic inflammation. A topical or transdermal composition containing vitamin D, one or more saccharide...
|
|
WO/2013/060098 |
Disclosed is a compound of (aminophenylamino)pyrimidyl benzamides and a synthesis method thereof. The compound has Btk-inhibition activity and can be used to treat autoimmune diseases, heteroimmune diseases, cancers or thromboembolic dis...
|
|
WO/2013/060714 |
The invention relates to the use of extracts from Filipendula for the treatment or prophylaxis of chronic pain conditions that have no identifiable organic causes.
|
|
WO/2013/058812 |
The present invention provides, in part, compositions and methods of targeted delivery of an agent or cells to islet endothelial cells in the pancreas using a novel islet-targeting molecule. Accordingly, one aspect of the present inventi...
|
|
WO/2013/057354 |
The present invention relates to the use of a composition comprising melatonin or a derivative thereof in a proportion of 2‑5% to 5% w/v for the production of a pharmaceutical composition for treating and/or preventing mucositis. The m...
|
